
Journal of Clinical Oncology

The Official Journal of the American Society of Clinical Oncology

Vol 13, No 9

September 1995

CONTENTS

- EDITORIAL: Pain Relief Into Practice: Rhetoric Without Reform** *Kathleen M. Foley* 2149
- EDITORIAL: Cost-Effectiveness Analysis: Sleeping With an Enemy or a Friend?**
Subhash C. Gulati and Jacob D. Bitran 2152
- EDITORIAL: Suramin and Prostate Cancer: Where Do We Go From Here?** *Jeffrey W. Clark
and Bruce A. Chabner* 2155

ORIGINAL REPORTS

- An Institutional Commitment to Pain Management** *Betty R. Ferrell, Grace E. Dean,
Marcia Grant, and Paul Coluzzi* 2158
- Economic Evaluation of a Randomized Clinical Trial Comparing Vinorelbine, Vinorelbine Plus
Cisplatin, and Vindesine Plus Cisplatin for Non-Small-Cell Lung Cancer** *Thomas J. Smith,
Bruce E. Hillner, Dierdre M. Neighbors, Paul A. McSorley, and Thierry Le Chevalier* 2166
- Phase I and Clinical Evaluation of a Pharmacologically Guided Regimen of Suramin in Patients
With Hormone-Refractory Prostate Cancer** *Mario A. Eisenberger, Victoria J. Sinibaldi,
Leonard M. Reyno, Rajeshwari Sridhara, Duncan I. Jodrell, Eleanor G. Zuhowski,
Katherine H. Tkaczuk, Mark H. Lowitt, Ramzi K. Hemady, Stephen C. Jacobs, David VanEcho,
and Merrill J. Egorin* 2174

Journal of Clinical Oncology (ISSN 0732-183X) is published monthly by W.B. Saunders Company. Corporate and Editorial Offices: The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399. Accounting and Circulation Offices: W.B. Saunders Company, 6277 Sea Harbor Dr, Orlando, FL 32887-4800. Second class postage paid at Orlando, FL 32862, and at additional mailing offices.

Editorial correspondence should be addressed to George P. Canellos, MD, *Journal of Clinical Oncology*, 454 Brookline Ave, Suite 28, Boston, MA 02115. Telephone: (617) 632-5150.

POSTMASTER: Send change of address to *Journal of Clinical Oncology*, c/o W.B. Saunders Company, 6277 Sea Harbor Dr, Orlando, FL 32887-4800.

Yearly subscription rates: United States and possessions: individual, \$190.00; institution, \$243.00; single issue, \$25.00. All other countries: individual, \$247.00; institution, \$290.00; single issue, \$25.00. Student and resident: United States and possessions: \$76.00, all other countries: \$88.00. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the *signature* of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription are on a prorated basis. Subscriptions are accepted on a calendar year basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability.

Development and Validation of a Pharmacokinetically Based Fixed Dosing Scheme for Suramin <i>Leonard M. Reyno, Merrill J. Egorin, Mario A. Eisenberger, Victoria J. Sinibaldi, Eleanor G. Zuhowski, and Rajeshwari Sridhara</i>	2187
Phase I Study of Suramin Given by Intermittent Infusion Without Adaptive Control in Patients With Advanced Cancer <i>Ken Kobayashi, Everett E. Vokes, Nicholas J. Vogelzang, Linda Janisch, Betty Soliven, and Mark J. Ratain</i>	2196
Prospective Evaluation of Hydrocortisone and Suramin in Patients With Androgen-Independent Prostate Cancer <i>W. Kevin Kelly, Tracy Curley, Christine Leibertz, Ann Dnistrian, Morton Schwartz, and Howard I. Scher</i>	2208
Suramin and Hydrocortisone: Determining Drug Efficacy in Androgen-Independent Prostate Cancer <i>W. Kevin Kelly, Howard I. Scher, Madhu Mazumdar, David Pfister, Tracy Curley, Christine Leibertz, Lee Cohen, Vaia Vlamis, Ann Dnistrian, and Morton Schwartz</i>	2214
Pharmacologic Variables Associated With the Development of Neurologic Toxicity in Patients Treated With Suramin <i>Roberto J. Bitton, William D. Figg, David J. Venzon, Marinos C. Dalakas, Christopher Bowden, Donna Headlee, Eddie Reed, Charles E. Myers, and Michael R. Cooper</i>	2223
Phase I Study of Paclitaxel and Topotecan in Patients With Advanced Tumors: A Cancer and Leukemia Group B Study <i>Rogério C. Lilenbaum, Mark J. Ratain, Antonius A. Miller, Jeffrey B. Hargis, Donna R. Hollis, Gary L. Rosner, Sheila M. O'Brien, Linda Brewster, Mark R. Green, and Richard L. Schilsky</i>	2230
Phase I Trial of Carboplatin and Infusional Cyclosporine in Advanced Malignancy <i>Robert J. Morgan, Jr, Kim Margolin, James Raschko, Steven Akman, Lucille Leong, George Somlo, Kevin Scanlon, Chul Ahn, Mary Carroll, and James H. Doroshow</i>	2238
Preirradiation Chemotherapy With Carboplatin and Etoposide in Newly Diagnosed Embryonal Pediatric CNS Tumors <i>Richard L. Heideman, Edward H. Kovnar, Stewart J. Kellie, Edwin C. Douglass, Amar J. Gajjar, Andrew W. Walter, James A. Langston, Jesse J. Jenkins, Yulan Li, Carol Greenwald, Robert A. Sanford, and Larry E. Kun</i>	2247
Stage I Testicular Seminoma: Results of Adjuvant Irradiation and Surveillance <i>P. Warde, M.K. Gospodarowicz, T. Panzarella, C.N. Catton, J.F.G. Sturgeon, M. Moore, P. Goodman, and M.A.S. Jewett</i>	2255
Biphasic Patterns of Memory Deficits Following Moderate-Dose Partial-Brain Irradiation: Neuropsychologic Outcome and Proposed Mechanisms <i>Carol Armstrong, James Ruffer, Benjamin Corn, Kelly DeVries, and Joan Mollman</i>	2263
Escalated MVAC With or Without Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for the Initial Treatment of Advanced Malignant Urothelial Tumors: Results of a Randomized Trial <i>Christopher J. Logothetis, Laury D. Finn, Terry Smith, Robert G. Kilbourn, Julie A. Ellerhorst, Alexander A. Zukiwski, Avishay Sella, Shi-Ming Tu, and Robert J. Amato</i>	2272

Evaluation of Reproductive Capacity in Germ Cell Tumor Patients Following Treatment With Cisplatin, Etoposide, and Bleomycin	<i>William T. Stephenson, Shelly M. Poirier, Leslie Rubin, and Lawrence H. Einhorn</i>	2278
Phase Ia/Ib Trial of Bispecific Antibody MDX-210 in Patients With Advanced Breast or Ovarian Cancer That Overexpresses the Proto-Oncogene HER-2/<i>neu</i>	<i>Frank H. Valone, Peter A. Kaufman, Paul M. Guyre, Lionel D. Lewis, Vincent Memoli, Yashwant Deo, Robert Graziano, Jan L. Fisher, Louise Meyer, Mary Mrozek-Orlowski, Kathleen Wardwell, Veronica Guyre, Theresa L. Morley, Christine Arvizu, and Michael W. Fanger</i>	2281
p53 Mutations in Benign Breast Tissue	<i>Robert Millikan, Barbara Hulka, Ann Thor, Yingchun Zhang, Susan Edgerton, Xiaoxing Zhang, Hong Pei, Mei He, Lester Wold, L. Joseph Melton, David Ballard, Kathleen Conway, and Edison T. Liu</i>	2293
Modulation of O⁶-Alkylguanine Alkyltransferase-Directed DNA Repair in Metastatic Colon Cancers	<i>James K.V. Willson, John R. Haaga, Joan E. Trey, Thomas A. Stellato, Nahida H. Gordon, and Stanton L. Gerson</i>	2301
Lymph Node Staging Standards in Gastric Cancer	<i>A.M.G. Bunt, P.C.W. Hogendoorn, C.J.H. van de Velde, J.A. Bruijn, and J. Hermans</i>	2309
Impact of Protracted Venous Infusion Fluorouracil With or Without Interferon Alfa-2b on Tumor Response, Survival, and Quality of Life in Advanced Colorectal Cancer	<i>Mark Hill, Andrew Norman, David Cunningham, Michael Findlay, Maggie Watson, Viola Nicolson, Andrew Webb, Gary Middleton, Fareeda Ahmed, Tamas Hickish, Marianne Nicolson, Mary O'Brien, Timothy Iveson, Angela Iveson, and Christopher Evans</i>	2317
Controlled Clinical Trial of Interferon-γ as Postoperative Surgical Adjuvant Therapy for Colon Cancer	<i>Martin Wiesenfeld, Michael J. O'Connell, H. Sam Wieand, Nick J. Gonchoroff, John H. Donohue, Robert J. Fitzgibbons, Jr, James E. Krook, James A. Mailliard, James B. Gerstner, and Richard Pazdur</i>	2324
Surgical Treatment of Spinal Cord Compression From Epidural Metastasis	<i>Narayan Sundaresan, Ved Prakash Sachdev, James F. Holland, Frank Moore, Max Sung, Paolo A. Paciucci, Li-Teh Wu, Kevin Kelligher, and Laura Hough</i>	2330
Role of Surgical Resection in Pelvic Ewing's Sarcoma	<i>S.P. Scully, H.T. Temple, R.J. O'Keefe, M.T. Scarborough, H.J. Mankin, and M.C. Gebhardt</i>	2336
Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Treated With Carboplatin and Etoposide	<i>Benjamin Sredni, Michael Albeck, Thomas Tichler, Adi Shani, Jeremy Shapira, Israel Bruderman, Rafael Catane, Bella Kaufman, and Yona Kalechman</i>	2342
Randomized Trial of Interferon Maintenance in Multiple Myeloma: A Study of the National Cancer Institute of Canada Clinical Trials Group	<i>G.P. Browman, D. Bergsagel, D. Sicheri, S. O'Reilly, K.S. Wilson, S. Rubin, A. Belch, C. Shustik, R. Barr, I. Walker, K. James, B. Zee, and D. Johnston</i>	2354

Prognostic Value of Size of Lymph Node Metastases in Patients With Cutaneous Melanoma <i>Antonio C. Buzaid, Lygia A. Tinoco, David Jendiroba, Z. Nora Tu, J. Jack Lee, Sewa S. Legha, Merrick I. Ross, Charles M. Balch, and Robert S. Benjamin</i>	2361
Patient Participation in Clinical Decision-Making for Treatment of T3 Laryngeal Cancer: A Comparison of State and Process Utilities <i>J. van der Donk, P.C. Levendag, A.J. Kuijpers, F.H.J. Roest, J.D.F. Habbema, C.A. Meeuwis, and P.I.M. Schmitz</i>	2369
Results of a Randomized Trial Comparing MVPP Chemotherapy With a Hybrid Regimen, ChIVPP/EVA, in the Initial Treatment of Hodgkin's Disease <i>J.A. Radford, D. Crowther, A.Z.S. Rohatiner, W.D.J. Ryder, R.K. Gupta, A. Oza, D.P. Deakin, S. Arnott, P.M. Wilkinson, R.D. James, R.J. Johnson, and T.A. Lister</i>	2379
Randomized Phase II Comparison of Standard CHOP With Weekly CHOP in Elderly Patients With Non-Hodgkin's Lymphoma <i>Ralph M. Meyer, George P. Browman, Martin L. Samosh, Ann M. Benger, Denise Bryant-Lukosius, W. Edwin C. Wilson, George L. Frank, Brian F. Leber, Marion S. Sternbach, Gary A. Foster, Peter Skingley, and Mark N. Levine</i>	2386
Survival of Patients With Resistant Hodgkin's Disease After Polyclonal Yttrium 90-Labeled Antiferritin Treatment <i>J.M. Herpst, J.L. Klein, P.K. Leichner, S.M. Quadri, and H.M. Vriesendorp</i>	2394
Immune-Mediated and Unusual Complications During Interferon Alfa Therapy in Chronic Myelogenous Leukemia <i>Stefan Sacchi, Hagop Kantarjian, Susan O'Brien, Philip R. Cohen, Sherry Pierce, and Moshe Talpaz</i>	2401
Oral Ondansetron for the Control of Cisplatin-Induced Delayed Emesis: A Large, Multicenter, Double-Blind, Randomized Comparative Trial of Ondansetron Versus Placebo <i>Rudolph M. Navari, Stefan Madajewicz, Norwood Anderson, Nerses S. Tchekmedyan, William Whaley, Harinder Garewal, Thomas M. Beck, Alex Y. Chang, Bernard Greenberg, Kenneth C. Caldwell, David H. Huffman, James R. Gould, Graham Carron, Michael Ossi, and Elaine M. Anderson</i>	2408
Persistence of Efficacy of Three Antiemetic Regimens and Prognostic Factors in Patients Undergoing Moderately Emetogenic Chemotherapy <i>the Italian Group for Antiemetic Research</i>	2417
Effect of Oral Clodronate on Metastatic Bone Pain: A Double-Blind, Placebo-Controlled Study <i>A.G. Robertson, N.S. Reed, and S.H. Ralston</i>	2427

REVIEW ARTICLES

Infectious and Immunosuppressive Complications of Purine Analog Therapy . . . <i>Bruce D. Cheson</i>	2431
---	------

Breaking Bad News: Consensus Guidelines for Medical Practitioners	<i>Afaf Girgis and Rob W. Sanson-Fisher</i>	2449
--	---	------

SPECIAL ARTICLES

Free-Riding and the Prisoner's Dilemma: Problems in Funding Economic Analyses of Phase III Cancer Clinical Trials	<i>Charles L. Bennett, Thomas J. Smith, Stephen L. George, Bruce E. Hillner, Stewart Fleishman, and Harvey B. Niell</i>	2457
Ethical Considerations in Oncology: Balancing the Interests of Patients, Oncologists, and Society	<i>Thomas J. Smith and Joann N. Bodurtha</i>	2464

SPECIAL DEPARTMENTS

Correspondence		2471
It Is Time to Stratify With Prognostic Factors for Hepatic Metastases	<i>Nicholas J. Petrelli</i>	
Perceptions of Cancer Patients and Their Physicians Involved in Phase I Clinical Trials	<i>Paul L. Weiden and Janet W. Appelbaum</i>	
Remarks on "Molecular Markers and Stem-Cell Transplants: Are They Made for Each Other?"	<i>Fernando Cabanillas</i>	
• In Reply	<i>Russell J. Schilder</i>	
Benefits of Epoetin Alfa Therapy in Anemic Cancer Patients Receiving Chemotherapy	<i>David H. Henry and Robert I. Abels</i>	
• In Reply	<i>Julie M. Vose and James O. Armitage</i>	
Loss of Activity of <i>Erwinia</i> Asparaginase on Repeat Applications	<i>Joachim Boos, U. Nowak-Göttl, H. Jürgens, G. Fleischhack, and U. Bode</i>	
• In Reply	<i>Salvatore P. Dibeneditto</i>	
Response and Control: Lessons From Oligodendroglioma	<i>J. Gregory Cairncross and Elizabeth A. Eisenhauer</i>	
Response of Meningeal Waldenström's Macroglobulinemia to 2-Chlorodeoxyadenosine ...	<i>Arthur I. Richards</i>	
Erratum		2476
ASCO Abstract Form:		B-1

Announcements	lxxxiii
Information for Contributors	xxi
Current Abstracts	xviii